|
|
|
|
European Biopharmaceutical Review |
| |
|
European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.
With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.
|
|
|
|
|
|
 |
Industry Events |
 |
2014 Biotech China
14-16 May 2014,
Jointly
organized by Nanjing Pushlong Business Management Co., Ltd. and more than 10
national associations, The All China Biotech Conference & Exhibition
(Biotech China) will be grandly held in Nanjing on May 14 - 16, 2014, creating
a platform for business and academic exchanges.
More info >> |
|
 |
News and Press Releases |
 |
Steve McCairns joins expanding PCI team as UK Director of Operations
Powys, Wales – March 17, 2014 - Packaging Coordinators, Inc. (PCI) is pleased to welcome Steve McCairns as Director of Operations for its UK business.
More info >> |
|
 |
White Papers |
 |
|
Case Study: Cmed’s Mobile Data Management Solution
Cmed Clinical Services
The trial presented to Cmed was a randomized, double blinded, placebo
and active controlled study to evaluate the cardiac safety of multiple
doses of [study drug] in health volunteers.
The pharmaceutical
company, who were into the second year of development of a potential
blockbuster compound for the treatment of chronic myelogenous leukaemia
(CML), were requested by the FDA to design a trial to provide
information on the cardiac safety of different dose levels of the study
drug in healthy adult volunteers. The primary objective of the study was
specifically to find the maximum tolerated dose before QTc levels
became unsafe. All development of the compound was put on hold until the
results of this study were submitted to the FDA and approval granted
for the compound to progress into full development.
More info >> |
|
|
